A citation-based method for searching scientific literature

Therese Vu, Rebecca Austin, Catherine Paine Kuhn, Claudia Bruedigam, Axia Song, Solene Guignes, Sebastien Jacquelin, Hayley S Ramshaw, Geoffrey R Hill, Angel F Lopez, Steven W Lane. Haematologica 2016
Times Cited: 5







List of co-cited articles
20 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Distinct roles for long-term hematopoietic stem cells and erythroid precursor cells in a murine model of Jak2V617F-mediated polycythemia vera.
Ann Mullally, Luke Poveromo, Rebekka K Schneider, Fatima Al-Shahrour, Steven W Lane, Benjamin L Ebert. Blood 2012
55
60

Depletion of Jak2V617F myeloproliferative neoplasm-propagating stem cells by interferon-α in a murine model of polycythemia vera.
Ann Mullally, Claudia Bruedigam, Luke Poveromo, Florian H Heidel, Amy Purdon, Therese Vu, Rebecca Austin, Dirk Heckl, Lawrence J Breyfogle, Catherine Paine Kuhn,[...]. Blood 2013
113
60

Physiological Jak2V617F expression causes a lethal myeloproliferative neoplasm with differential effects on hematopoietic stem and progenitor cells.
Ann Mullally, Steven W Lane, Brian Ball, Christine Megerdichian, Rachel Okabe, Fatima Al-Shahrour, Mahnaz Paktinat, J Erika Haydu, Elizabeth Housman, Allegra M Lord,[...]. Cancer Cell 2010
274
60

Myeloproliferative neoplasm animal models.
Ann Mullally, Steven W Lane, Kristina Brumme, Benjamin L Ebert. Hematol Oncol Clin North Am 2012
25
60

Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis.
Ross L Levine, Martha Wadleigh, Jan Cools, Benjamin L Ebert, Gerlinde Wernig, Brian J P Huntly, Titus J Boggon, Iwona Wlodarska, Jennifer J Clark, Sandra Moore,[...]. Cancer Cell 2005
60

Pegylated interferon-alfa-2a induces complete hematologic and molecular responses with low toxicity in polycythemia vera.
Jean-Jacques Kiladjian, Bruno Cassinat, Sylvie Chevret, Pascal Turlure, Nathalie Cambier, Murielle Roussel, Sylvia Bellucci, Bernard Grandchamp, Christine Chomienne, Pierre Fenaux. Blood 2008
413
40

Pegylated interferon alfa-2a yields high rates of hematologic and molecular response in patients with advanced essential thrombocythemia and polycythemia vera.
Alfonso Quintás-Cardama, Hagop Kantarjian, Taghi Manshouri, Rajyalakshmi Luthra, Zeev Estrov, Sherry Pierce, Mary Ann Richie, Gautam Borthakur, Marina Konopleva, Jorge Cortes,[...]. J Clin Oncol 2009
285
40

Neuropathy of haematopoietic stem cell niche is essential for myeloproliferative neoplasms.
Lorena Arranz, Abel Sánchez-Aguilera, Daniel Martín-Pérez, Joan Isern, Xavier Langa, Alexandar Tzankov, Pontus Lundberg, Sandra Muntión, Yi-Shiuan Tzeng, Dar-Ming Lai,[...]. Nature 2014
291
40

The JAK2 V617F mutation occurs in hematopoietic stem cells in polycythemia vera and predisposes toward erythroid differentiation.
Catriona H M Jamieson, Jason Gotlib, Jeffrey A Durocher, Mark P Chao, M Rajan Mariappan, Marla Lay, Carol Jones, James L Zehnder, Stan L Lilleberg, Irving L Weissman. Proc Natl Acad Sci U S A 2006
203
40

Improved targeting of JAK2 leads to increased therapeutic efficacy in myeloproliferative neoplasms.
Neha Bhagwat, Priya Koppikar, Matthew Keller, Sachie Marubayashi, Kaitlyn Shank, Raajit Rampal, Jun Qi, Maria Kleppe, Hardik J Patel, Smit K Shah,[...]. Blood 2014
89
40

The effect of long-term ruxolitinib treatment on JAK2p.V617F allele burden in patients with myelofibrosis.
Michael Deininger, Jerald Radich, Timothy C Burn, Reid Huber, Dilan Paranagama, Srdan Verstovsek. Blood 2015
126
40

Loss of Ezh2 synergizes with JAK2-V617F in initiating myeloproliferative neoplasms and promoting myelofibrosis.
Takafumi Shimizu, Lucia Kubovcakova, Ronny Nienhold, Jakub Zmajkovic, Sara C Meyer, Hui Hao-Shen, Florian Geier, Stephan Dirnhofer, Paola Guglielmelli, Alessandro M Vannucchi,[...]. J Exp Med 2016
77
40

Myeloproliferative neoplasia remodels the endosteal bone marrow niche into a self-reinforcing leukemic niche.
Koen Schepers, Eric M Pietras, Damien Reynaud, Johanna Flach, Mikhail Binnewies, Trit Garg, Amy J Wagers, Edward C Hsiao, Emmanuelle Passegué. Cell Stem Cell 2013
421
40

The loss of Ezh2 drives the pathogenesis of myelofibrosis and sensitizes tumor-initiating cells to bromodomain inhibition.
Goro Sashida, Changshan Wang, Takahisa Tomioka, Motohiko Oshima, Kazumasa Aoyama, Akinori Kanai, Makiko Mochizuki-Kashio, Hironori Harada, Kazuya Shimoda, Atsushi Iwama. J Exp Med 2016
70
40

Involvement of various hematopoietic-cell lineages by the JAK2V617F mutation in polycythemia vera.
Takefumi Ishii, Edward Bruno, Ronald Hoffman, Mingjiang Xu. Blood 2006
116
40


A humanized bone marrow ossicle xenotransplantation model enables improved engraftment of healthy and leukemic human hematopoietic cells.
Andreas Reinisch, Daniel Thomas, M Ryan Corces, Xiaohua Zhang, Dita Gratzinger, Wan-Jen Hong, Katharina Schallmoser, Dirk Strunk, Ravindra Majeti. Nat Med 2016
136
40

Critical requirement for Stat5 in a mouse model of polycythemia vera.
Dongqing Yan, Robert E Hutchison, Golam Mohi. Blood 2012
97
40

A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera.
Chloé James, Valérie Ugo, Jean-Pierre Le Couédic, Judith Staerk, François Delhommeau, Catherine Lacout, Loïc Garçon, Hana Raslova, Roland Berger, Annelise Bennaceur-Griscelli,[...]. Nature 2005
40

Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders.
E Joanna Baxter, Linda M Scott, Peter J Campbell, Clare East, Nasios Fourouclas, Soheila Swanton, George S Vassiliou, Anthony J Bench, Elaine M Boyd, Natasha Curtin,[...]. Lancet 2005
40

The thrombopoietin receptor, MPL, is critical for development of a JAK2V617F-induced myeloproliferative neoplasm.
Veena Sangkhae, S Leah Etheridge, Kenneth Kaushansky, Ian S Hitchcock. Blood 2014
57
20

JAK2V617F homozygosity arises commonly and recurrently in PV and ET, but PV is characterized by expansion of a dominant homozygous subclone.
Anna L Godfrey, Edwin Chen, Francesca Pagano, Christina A Ortmann, Yvonne Silber, Beatriz Bellosillo, Paola Guglielmelli, Claire N Harrison, John T Reilly, Frank Stegelmann,[...]. Blood 2012
77
20


JAK2 or CALR mutation status defines subtypes of essential thrombocythemia with substantially different clinical course and outcomes.
Elisa Rumi, Daniela Pietra, Virginia Ferretti, Thorsten Klampfl, Ashot S Harutyunyan, Jelena D Milosevic, Nicole C C Them, Tiina Berg, Chiara Elena, Ilaria C Casetti,[...]. Blood 2014
408
20

Targeting megakaryocytic-induced fibrosis in myeloproliferative neoplasms by AURKA inhibition.
Qiang Jeremy Wen, Qiong Yang, Benjamin Goldenson, Sébastien Malinge, Terra Lasho, Rebekka K Schneider, Lawrence J Breyfogle, Rachael Schultz, Laure Gilles, Priya Koppikar,[...]. Nat Med 2015
108
20

Effect of mutation order on myeloproliferative neoplasms.
Christina A Ortmann, David G Kent, Jyoti Nangalia, Yvonne Silber, David C Wedge, Jacob Grinfeld, E Joanna Baxter, Charles E Massie, Elli Papaemmanuil, Suraj Menon,[...]. N Engl J Med 2015
339
20

Critical role of thrombopoietin in maintaining adult quiescent hematopoietic stem cells.
Hong Qian, Natalija Buza-Vidas, Craig D Hyland, Christina T Jensen, Jennifer Antonchuk, Robert Månsson, Lina A Thoren, Marja Ekblom, Warren S Alexander, Sten Eirik W Jacobsen. Cell Stem Cell 2007
363
20

Mutation in TET2 in myeloid cancers.
François Delhommeau, Sabrina Dupont, Véronique Della Valle, Chloé James, Severine Trannoy, Aline Massé, Olivier Kosmider, Jean-Pierre Le Couedic, Fabienne Robert, Antonio Alberdi,[...]. N Engl J Med 2009
20

Ruxolitinib is an effective treatment for CALR-positive patients with myelofibrosis.
Paola Guglielmelli, Giada Rotunno, Costanza Bogani, Carmela Mannarelli, Laura Giunti, Aldesia Provenzano, Sabrina Giglio, Matthew Squires, Viktoriya Stalbovskaya, Prashanth Gopalakrishna,[...]. Br J Haematol 2016
32
20

The constitutive mobilization of bone marrow-repopulating cells into the peripheral blood in idiopathic myelofibrosis.
Mingjiang Xu, Edward Bruno, Joseph Chao, Hongyu Ni, Valerie Lindgren, Rafael Nunez, Nadim Mahmud, Guido Finazzi, Steven M Fruchtman, Uday Popat,[...]. Blood 2005
47
20

Calreticulin mutants in mice induce an MPL-dependent thrombocytosis with frequent progression to myelofibrosis.
Caroline Marty, Christian Pecquet, Harini Nivarthi, Mira El-Khoury, Ilyas Chachoua, Micheline Tulliez, Jean-Luc Villeval, Hana Raslova, Robert Kralovics, Stefan N Constantinescu,[...]. Blood 2016
182
20

Mutant Calreticulin Requires Both Its Mutant C-terminus and the Thrombopoietin Receptor for Oncogenic Transformation.
Shannon Elf, Nouran S Abdelfattah, Edwin Chen, Javier Perales-Patón, Emily A Rosen, Amy Ko, Fabian Peisker, Natalie Florescu, Silvia Giannini, Ofir Wolach,[...]. Cancer Discov 2016
179
20

Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence.
Giulio Genovese, Anna K Kähler, Robert E Handsaker, Johan Lindberg, Samuel A Rose, Samuel F Bakhoum, Kimberly Chambert, Eran Mick, Benjamin M Neale, Menachem Fromer,[...]. N Engl J Med 2014
20

Age-related clonal hematopoiesis associated with adverse outcomes.
Siddhartha Jaiswal, Pierre Fontanillas, Jason Flannick, Alisa Manning, Peter V Grauman, Brenton G Mar, R Coleman Lindsley, Craig H Mermel, Noel Burtt, Alejandro Chavez,[...]. N Engl J Med 2014
20

Loss of TET2 has dual roles in murine myeloproliferative neoplasms: disease sustainer and disease accelerator.
Takuro Kameda, Kotaro Shide, Takumi Yamaji, Ayako Kamiunten, Masaaki Sekine, Yasuhiro Taniguchi, Tomonori Hidaka, Yoko Kubuki, Haruko Shimoda, Kousuke Marutsuka,[...]. Blood 2015
58
20

Clonal hematopoiesis of indeterminate potential and its distinction from myelodysplastic syndromes.
David P Steensma, Rafael Bejar, Siddhartha Jaiswal, R Coleman Lindsley, Mikkael A Sekeres, Robert P Hasserjian, Benjamin L Ebert. Blood 2015
20

Genetic variation at MECOM, TERT, JAK2 and HBS1L-MYB predisposes to myeloproliferative neoplasms.
William Tapper, Amy V Jones, Robert Kralovics, Ashot S Harutyunyan, Katerina Zoi, William Leung, Anna L Godfrey, Paola Guglielmelli, Alison Callaway, Daniel Ward,[...]. Nat Commun 2015
120
20

Notch-dependent repression of miR-155 in the bone marrow niche regulates hematopoiesis in an NF-κB-dependent manner.
Lin Wang, Huajia Zhang, Sonia Rodriguez, Liyun Cao, Jonathan Parish, Christen Mumaw, Amy Zollman, Malgorzata M Kamoka, Jian Mu, Danny Z Chen,[...]. Cell Stem Cell 2014
136
20

The role of Smad signaling in hematopoiesis.
Jonas Larsson, Stefan Karlsson. Oncogene 2005
122
20

JAK2V617F expression in mice amplifies early hematopoietic cells and gives them a competitive advantage that is hampered by IFNα.
Salma Hasan, Catherine Lacout, Caroline Marty, Marie Cuingnet, Eric Solary, William Vainchenker, Jean-Luc Villeval. Blood 2013
104
20

Conditional deletion of Jak2 reveals an essential role in hematopoiesis throughout mouse ontogeny: implications for Jak2 inhibition in humans.
Sung O Park, Heather L Wamsley, Kyungmi Bae, Zhongbo Hu, Xiaomiao Li, Se-woon Choe, William B Slayton, S Paul Oh, Kay-Uwe Wagner, Peter P Sayeski. PLoS One 2013
50
20

Activation of the thrombopoietin receptor by mutant calreticulin in CALR-mutant myeloproliferative neoplasms.
Marito Araki, Yinjie Yang, Nami Masubuchi, Yumi Hironaka, Hiraku Takei, Soji Morishita, Yoshihisa Mizukami, Shin Kan, Shuichi Shirane, Yoko Edahiro,[...]. Blood 2016
178
20

Leukemic blasts in transformed JAK2-V617F-positive myeloproliferative disorders are frequently negative for the JAK2-V617F mutation.
Alexandre Theocharides, Marjorie Boissinot, François Girodon, Richard Garand, Soon-Siong Teo, Eric Lippert, Pascaline Talmant, Andre Tichelli, Sylvie Hermouet, Radek C Skoda. Blood 2007
240
20

VEGF expression correlates with microvessel density in Philadelphia chromosome-negative chronic myeloproliferative disorders.
Umberto Gianelli, Claudia Vener, Paola Rafaniello Raviele, Federica Savi, Francesco Somalvico, Rossella Calori, Alesndra Iurlo, Franca Radaelli, Elisa Fermo, Paolo Bucciarelli,[...]. Am J Clin Pathol 2007
40
20

Minimal residual disease and normalization of the bone marrow after long-term treatment with alpha-interferon2b in polycythemia vera. A report on molecular response patterns in seven patients in sustained complete hematological remission.
Thomas Stauffer Larsen, Michael Boe Møller, Karin de Stricker, Peter Nørgaard, Jan Samuelsson, Claus Marcher, Morten T Andersen, Ole Weis Bjerrum, Hans Carl Hasselbalch. Hematology 2009
65
20

Clonal dynamics of native haematopoiesis.
Jianlong Sun, Azucena Ramos, Brad Chapman, Jonathan B Johnnidis, Linda Le, Yu-Jui Ho, Allon Klein, Oliver Hofmann, Fernando D Camargo. Nature 2014
511
20

Single-cell RNA sequencing reveals molecular and functional platelet bias of aged haematopoietic stem cells.
Amit Grover, Alejandra Sanjuan-Pla, Supat Thongjuea, Joana Carrelha, Alice Giustacchini, Adriana Gambardella, Iain Macaulay, Elena Mancini, Tiago C Luis, Adam Mead,[...]. Nat Commun 2016
146
20

Lipocalin produced by myelofibrosis cells affects the fate of both hematopoietic and marrow microenvironmental cells.
Min Lu, Lijuan Xia, Yen-Chun Liu, Tsivia Hochman, Laetizia Bizzari, Daniel Aruch, Jane Lew, Rona Weinberg, Judith D Goldberg, Ronald Hoffman. Blood 2015
50
20

Indication and management of allogeneic stem cell transplantation in primary myelofibrosis: a consensus process by an EBMT/ELN international working group.
N M Kröger, J H Deeg, E Olavarria, D Niederwieser, A Bacigalupo, T Barbui, A Rambaldi, R Mesa, A Tefferi, M Griesshammer,[...]. Leukemia 2015
183
20

Transformation from committed progenitor to leukaemia stem cell initiated by MLL-AF9.
Andrei V Krivtsov, David Twomey, Zhaohui Feng, Matthew C Stubbs, Yingzi Wang, Joerg Faber, Jason E Levine, Jing Wang, William C Hahn, D Gary Gilliland,[...]. Nature 2006
20


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.